作者: Tania Fleitas , Maider Ibarrola-Villava , Gloria Ribas , Andrés Cervantes
DOI: 10.1016/J.CTRV.2016.07.007
关键词:
摘要: This article will review the impact of recently developed MassARRAY technology on our understanding cancer biology and treatment. Analysis somatic mutations is a useful tool in selecting personalized therapy, for predicting outcome many solid tumors. Here, we literature application (Sequenom Hamburg, Germany) to determine mutation profile tumors from patients. We summarize use commercially available panels - such as OncoCarta™ or other combinations their concordance with results obtained by using technologies, next generation sequencing.